NYSE:DVA - Davita Stock Price, Price Target & More

$63.30 +0.45 (+0.72 %)

(As of 04/26/2018 01:17 AM ET)

Previous Close$63.30

Today's Range$61.92 - $63.4850

52-Week Range$52.51 - $80.71

Volume1.41 million shs

Average Volume1.55 million shs

Market Capitalization$11.48 billion

P/E Ratio19.07

Dividend YieldN/A

Beta1.09

About Davita (NYSE:DVA)

DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. Its DMG division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts. Its segments include U.S. dialysis and related lab services, DMG, and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2016, it had operated or provided administrative services to 154 outpatient dialysis centers.

Receive DVA News and Ratings via Email

Sign-up to receive the latest news and ratings for DVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified

Sub-IndustryHealth Care Services

SectorMedical

SymbolNYSE:DVA

CUSIP23918K10

Webwww.davita.com

Phone303-405-2100

Debt

Debt-to-Equity Ratio1.87%

Current Ratio2.88%

Quick Ratio2.82%

Price-To-Earnings

Trailing P/E Ratio19.07

Forward P/E Ratio15.22

P/E Growth0.91

Sales & Book Value

Annual Sales$10.88 billion

Price / Sales1.06

Cash Flow$7.7289 per share

Price / Cash8.19

Book Value$26.66 per share

Price / Book2.37

Profitability

EPS (Most Recent Fiscal Year)$3.32

Net Income$663.61 million

Net Margins4.65%

Return on Equity12.86%

Return on Assets3.43%

Miscellaneous

Employees74,500

Outstanding Shares182,000,000

How to Become a New Pot Stock Millionaire

Davita (NYSE:DVA) Frequently Asked Questions

What is Davita's stock symbol?

Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."

How will Davita's stock buyback program work?

Davita declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, October 11th 2017, which allows the company to repurchase $1,500,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

How were Davita's earnings last quarter?

Davita Inc (NYSE:DVA) released its quarterly earnings data on Tuesday, February, 13th. The company reported $0.92 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.94 by $0.02. The company earned $2.78 billion during the quarter, compared to analyst estimates of $3.90 billion. Davita had a net margin of 4.65% and a return on equity of 12.86%. During the same quarter in the prior year, the company earned $0.98 earnings per share. View Davita's Earnings History.

When is Davita's next earnings date?

Davita is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Davita.

What price target have analysts set for DVA?

11 Wall Street analysts have issued twelve-month target prices for Davita's shares. Their predictions range from $60.00 to $97.00. On average, they expect Davita's stock price to reach $79.00 in the next twelve months. View Analyst Ratings for Davita.

Who are some of Davita's key competitors?

Some companies that are related to Davita include Fresenius Medical Care (FMS), Tivity Health (TVTY), American Renal Associates (ARA), Catasys (CATS), Caladrius Biosciences (CLBS), BioRestorative Therapies (BRTX), Pacific Health Care Organization (PFHO), CNS Response (MYND), Hooper Holmes (HPHW) and American Caresource (GNOW).

Who are Davita's key executives?

Davita's management team includes the folowing people:

Kent J. Thiry, Chairman of the Board (Age 61)
James K. Hilger, Interim Chief Financial Officer, Chief Accounting Officer (Age 55)
Joel Ackerman, Chief Financial Officer (Age 51)
Robert Lang, President, International Business
Javier J. Rodriguez, Chief Executive Officer - Kidney Care (Age 46)
Jeanine M. Jiganti, Chief Compliance Officer (Age 57)
LeAnne M. Zumwalt, Group Vice President - purchasing and government affairs (Age 58)
Kathleen Alyce Waters, Chief Legal Officer (Age 49)
Peter T. Grauer, Lead Director, Independent Director (Age 71)
Pamela M. Arway, Independent Director (Age 63)

Has Davita been receiving favorable news coverage?

News articles about DVA stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Davita earned a media sentiment score of 0.11 on Accern's scale. They also gave press coverage about the company an impact score of 45.97 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Davita?

Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Davita's stock price today?

One share of DVA stock can currently be purchased for approximately $63.30.

How big of a company is Davita?

Davita has a market capitalization of $11.48 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. Davita employs 74,500 workers across the globe.

How can I contact Davita?

Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]

MarketBeat Community Rating for Davita (DVA)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		333 (Vote Outperform)
Underperform Votes:		356 (Vote Underperform)
Total Votes:		689

MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Davita (NYSE:DVA) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

11 Wall Street analysts have issued ratings and price targets for Davita in the last 12 months. Their average twelve-month price target is $79.00, suggesting that the stock has a possible upside of 24.80%. The high price target for DVA is $97.00 and the low price target for DVA is $60.00. There are currently 1 sell rating, 4 hold ratings, 4 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Hold
Consensus Rating Score:	2.64	2.64	2.64	2.00
Ratings Breakdown:	1 Sell Rating(s) 4 Hold Rating(s) 4 Buy Rating(s) 2 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 4 Buy Rating(s) 2 Strong Buy Rating(s)	1 Sell Rating(s) 4 Hold Rating(s) 4 Buy Rating(s) 2 Strong Buy Rating(s)	2 Sell Rating(s) 6 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$79.00	$79.00	$78.2222	$65.00
Price Target Upside:	24.80% upside	5.86% upside	2.26% downside	9.52% upside

Davita (NYSE:DVA) Consensus Price Target History

Price Target History for Davita (NYSE:DVA)

Davita (NYSE:DVA) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/14/2018	SunTrust Banks	Reiterated Rating	Hold	$80.00	Medium
2/13/2018	Robert W. Baird	Set Price Target	Buy	$97.00	High
1/11/2018	Bank of America	Reiterated Rating	Buy	$85.00 -> $92.00	High
12/11/2017	Citigroup	Upgrade	Neutral -> Buy	$67.71 -> $82.00	Medium
12/7/2017	JPMorgan Chase	Boost Price Target	Outperform -> Strong-Buy	$4.90 -> $84.00	Low
12/7/2017	Raymond James	Upgrade	Outperform -> Strong-Buy	$65.00 -> $84.00	High
12/6/2017	KeyCorp	Reiterated Rating	Hold		Low
11/8/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$64.00 -> $60.00	N/A
10/23/2017	Wolfe Research	Upgrade	Market Perform -> Outperform		N/A
8/3/2017	Jefferies Group	Reiterated Rating	Hold	$70.00	Medium
5/25/2017	Goldman Sachs	Reiterated Rating	Sell	$62.00	High
11/1/2016	Wells Fargo	Reiterated Rating	Outperform		N/A

(Data available from 4/26/2016 forward)

Davita (NYSE:DVA) Earnings History and Estimates Chart

Earnings by Quarter for Davita (NYSE:DVA)

Davita (NYSE:DVA) Earnings Estimates

2018 EPS Consensus Estimate: $4.00
2019 EPS Consensus Estimate: $4.48

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.88	$0.93	$0.91
Q2 2018	2	$0.95	$1.04	$1.00
Q3 2018	2	$1.03	$1.04	$1.04
Q4 2018	2	$1.01	$1.12	$1.07
Q1 2019	2	$1.00	$1.04	$1.02
Q2 2019	2	$1.06	$1.15	$1.11
Q3 2019	2	$1.15	$1.17	$1.16
Q4 2019	2	$1.16	$1.22	$1.19

Davita (NYSE DVA) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018		$0.93					N/A
2/13/2018	Q4 2017	$0.94	$0.92	$3.8959 billion	$2.7809 billion	View	Listen
11/7/2017	Q3 2017	$0.94	$0.81	$3.9076 billion	$3.9228 billion	View	N/A
8/1/2017	Q2 2017	$0.90	$0.92	$3.8170 billion	$3.8775 billion	View	Listen
5/2/2017	Q1 2017	$0.8150	$0.79	$3.6882 billion	$3.6973 billion	View	Listen
2/16/2017	Q4 2016	$0.91	$0.98	$3.74 billion	$3.7157 billion	View	Listen
11/2/2016	Q316	$0.94	$0.95	$3.72 billion	$3.73 billion	View	Listen
8/8/2016	Q216	$0.98	$1.01	$3.67 billion	$3.72 billion	View	Listen
5/4/2016	Q116	$0.86	$0.92	$3.51 billion	$3.58 billion	View	Listen
2/11/2016	Q415	$0.97	$1.01	$3.50 billion	$3.5336 billion	View	Listen
11/3/2015	Q315	$0.97	$1.00	$3.46 billion	$3.5257 billion	View	Listen
8/4/2015	Q215	$0.95	$0.95	$3.37 billion	$3.4346 billion	View	Listen
5/4/2015	Q115	$0.86	$0.86	$3.25 billion	$3.2880 billion	View	Listen
2/12/2015	Q414	$0.89	$0.96	$3.26 billion	$3.3280 billion	View	Listen
11/6/2014	Q314	$0.91	$0.90	$3.19 billion	$3.2518 billion	View	Listen
7/31/2014	Q214	$0.88	$0.95	$3.10 billion	$3.1725 billion	View	Listen
5/1/2014	Q1	$0.87	$0.85	$3.0230 billion	$3.0428 billion	View	Listen
2/11/2014	Q413	$1.91	$0.99	$2.92 billion	$3.06 billion	View	Listen
11/5/2013	Q313	$0.96	$0.98	$2.93 billion	$2.9996 billion	View	Listen
8/6/2013	Q2 2013	$1.84	$1.84	$2.88 billion	$2.8717 billion	View	Listen
5/7/2013	Q1 2013	$1.80	$1.84	$2.78 billion	$2.8296 billion	View	Listen
2/14/2013	Q4 2012	$1.60	$1.85	$2.40 billion	$2.48 billion	View	Listen
10/30/2012		$1.55	$1.56			View	N/A
8/1/2012		$1.47	$1.49			View	N/A
5/1/2012	Q1 2012	$0.73	$0.73			View	N/A
2/16/2012		$1.49	$1.58			View	N/A
11/3/2011		$1.46	$1.45			View	N/A
8/3/2011		$1.14	$1.17			View	N/A
5/2/2011		$0.95	$0.96			View	N/A
2/10/2011		$1.12	$0.70			View	N/A
11/4/2010	Q3 2010	$0.57	$0.57			View	N/A
8/2/2010	Q2 2010	$0.54	$0.53			View	N/A
4/27/2010	Q1 2010	$0.52	$0.52			View	N/A
2/10/2010	Q4 2009	$0.53	$0.53			View	N/A
11/3/2009	Q3 2009	$0.50	$0.53			View	N/A
8/4/2009	Q2 2009	$0.48	$0.51			View	N/A
4/27/2009	Q1 2009	$0.45	$0.46			View	N/A
2/10/2009	Q4 2008	$0.45	$0.47			View	N/A
11/3/2008	Q3 2008	$0.44	$0.44			View	N/A
8/4/2008	Q2 2008	$0.42	$0.45			View	N/A
4/29/2008	Q1 2008	$0.39	$0.40			View	N/A
2/13/2008	Q4 2007	$0.40	$0.40			View	N/A

(Earnings results data provided by Zacks Investment Research)

Davita (NYSE:DVA) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Davita (NYSE DVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 85.77%

Insider Trading History for Davita (NYSE:DVA)

Institutional Ownership by Quarter for Davita (NYSE:DVA)

Davita (NYSE DVA) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/16/2018	James K Hilger	Insider	Sell	3,572	$78.95	$282,009.40	33,649
12/11/2017	Charles Berg	Insider	Sell	7,048	$69.24	$488,003.52	5,359
12/8/2017	Kent J Thiry	Chairman	Sell	81,800	$68.04	$5,565,672.00
12/8/2017	Leanne M Zumwalt	VP	Sell	949	$68.19	$64,712.31	12,423
12/7/2017	James K Hilger	Insider	Sell	5,608	$69.46	$389,531.68	47,649
12/7/2017	Javier Rodriguez	CEO	Sell	22,532	$67.48	$1,520,459.36	210,317
5/15/2017	Javier Rodriguez	CEO	Sell	1,294	$66.21	$85,675.74	99,111
5/9/2017	Charles Berg	Director	Sell	8,414	$65.80	$553,641.20	34,719
5/4/2017	William L Roper	Director	Sell	12,994	$65.89	$856,174.66	45,277
8/9/2016	Michael David Staffieri	COO	Sell	20,262	$73.09	$1,480,949.58	52,279
7/11/2016	Jeanine Marie Jiganti	Insider	Sell	1,291	$78.51	$101,356.41	5,716
7/1/2016	Jeanine Marie Jiganti	Insider	Sell	4,620	$77.45	$357,819.00	7,590
5/25/2016	Pamela M Arway	Director	Sell	10,824	$77.16	$835,179.84	36,394
5/23/2016	James K Hilger	CFO	Sell	3,416	$76.79	$262,314.64	29,147
5/20/2016	Kent J Thiry	CEO	Sell	32,880	$76.99	$2,531,431.20	39,184
5/17/2016	Dennis Kogod	CEO	Sell	17,700	$77.35	$1,369,095.00	18,766
5/17/2016	Leanne M Zumwalt	VP	Sell	538	$77.08	$41,469.04	8,585
5/16/2016	James K Hilger	CFO	Sell	3,983	$75.59	$301,074.97	21,130
5/16/2016	Javier Rodriguez	CEO	Sell	36,466	$75.44	$2,750,995.04	64,264
5/16/2016	Michael David Staffieri	COO	Sell	4,934	$75.69	$373,454.46	12,279
5/12/2016	Roger Valine	Director	Sell	8,220	$76.34	$627,514.80	18,324
5/10/2016	Dennis Kogod	CEO	Sell	40,048	$76.25	$3,053,660.00	92,716
5/6/2016	John M Nehra	Director	Sell	16,314	$75.56	$1,232,685.84	36,665
4/11/2016	Javier Rodriguez	CEO	Sell	89,912	$73.51	$6,609,431.12	317,397
3/21/2016	Dennis Kogod	CEO	Sell	13,455	$72.12	$970,374.60	92,716
2/29/2016	Pamela M Arway	Director	Sell	9,026	$66.00	$595,716.00	36,070
2/23/2016	Leanne M. Zumwalt	VP	Sell	14,587	$64.25	$937,214.75
2/16/2016	Dennis Kogod	CEO	Sell	33,290	$61.99	$2,063,647.10	120,816
1/13/2016	Christopher James Schnarr	Insider	Buy	5,000	$0.68	$3,400.00
1/11/2016	Christopher James Schnarr	Insider	Buy	10,000	$0.60	$6,000.00
12/17/2015	Laura Mildenberger	insider	Sell	1,440	$68.14	$98,121.60	8,447
9/22/2015	Kim M. Rivera	insider	Sell	40,037	$75.48	$3,021,992.76	7,438
8/17/2015	Carol Anthony Davidson	Director	Sell	4,038	$79.93	$322,757.34
6/4/2015	Robert J Margolis	Chairman	Sell	31,400	$83.39	$2,618,446.00
5/28/2015	Michael David Staffieri	COO	Sell	9,050	$84.07	$760,833.50
5/19/2015	Robert J Margolis	Chairman	Sell	15,700	$83.22	$1,306,554.00
5/18/2015	James K Hilger	CFO	Sell	3,983	$82.10	$327,004.30
5/18/2015	Michael David Staffieri	COO	Sell	2,047	$82.03	$167,915.41
5/18/2015	Robert J Margolis	Chairman	Sell	15,700	$82.24	$1,291,168.00
5/11/2015	James K Hilger	CFO	Sell	8,267	$82.00	$677,894.00
5/11/2015	Jeanine Marie Jiganti	Insider	Sell	2,481	$81.95	$203,317.95
5/11/2015	John M Nehra	Director	Sell	12,278	$81.85	$1,004,954.30
4/21/2015	Robert J Margolis	Chairman	Sell	31,400	$82.40	$2,587,360.00
4/7/2015	Robert J Margolis	Chairman	Sell	15,700	$82.15	$1,289,755.00
4/6/2015	Robert J Margolis	Chairman	Sell	15,700	$81.49	$1,279,393.00
3/27/2015	Robert J Margolis	Chairman	Sell	31,400	$81.18	$2,549,052.00
3/12/2015	Robert J Margolis	Chairman	Sell	107,374	$79.24	$8,508,315.76
2/27/2015	Robert J Margolis	Chairman	Sell	21,000	$74.29	$1,560,090.00
2/19/2015	Robert J Margolis	Chairman	Sell	21,000	$73.12	$1,535,520.00
1/30/2015	Robert J Margolis	Chairman	Sell	31,400	$75.48	$2,370,072.00
1/23/2015	Michael David Staffieri	COO	Sell	21,869	$76.05	$1,663,137.45
1/16/2015	Robert J Margolis	Chairman	Sell	31,400	$74.92	$2,352,488.00
1/8/2015	Kim M Rivera	Insider	Sell	1,111	$75.10	$83,436.10
12/30/2014	Robert J Margolis	Chairman	Sell	31,400	$76.09	$2,389,226.00
12/29/2014	Robert J Margolis	Chairman	Sell	15,700	$76.09	$1,194,613.00
12/19/2014	Laura Mildenberger	Insider	Sell	1,446	$75.50	$109,173.00
12/18/2014	Robert J Margolis	Chairman	Sell	31,400	$74.67	$2,344,638.00
12/3/2014	Robert J Margolis	Chairman	Sell	31,400	$75.80	$2,380,120.00
12/1/2014	Kim M Rivera	Insider	Sell	6,503	$76.08	$494,748.24
11/21/2014	Robert J Margolis	Chairman	Sell	31,400	$75.08	$2,357,512.00
11/11/2014	Kent J Thiry	CEO	Sell	344,938	$74.52	$25,704,779.76
11/11/2014	Robert J Margolis	Chairman	Sell	250,000	$75.09	$18,772,500.00
11/10/2014	Berkshire Hathaway Inc	Major Shareholder	Buy	944,418	$74.11	$69,990,817.98
11/7/2014	R. Ted Weschler	Major Shareholder	Buy	820,018	$74.10	$60,763,333.80
11/3/2014	Roger Valine	Director	Sell	7,185	$77.85	$559,352.25
9/16/2014	John M Nehra	Director	Sell	20,000	$73.91	$1,478,200.00
9/8/2014	Kim M Rivera	Insider	Sell	1,111	$74.25	$82,491.75
8/27/2014	Leanne M Zumwalt	VP	Sell	3,214	$74.57	$239,667.98
8/11/2014	Jeanine Marie Jiganti	Insider	Sell	2,500	$72.14	$180,350.00
6/11/2014	Kim M Rivera	Insider	Sell	5,929	$71.05	$421,255.45
5/29/2014	Laura Mildenberger	Insider	Sell	5,080	$69.99	$355,549.20
5/16/2014	Dennis Kogod	COO	Sell	18,750	$67.30	$1,261,875.00	40,874
5/16/2014	Kent Thiry	CEO	Sell	17,600	$67.41	$1,186,416.00	247,950
5/15/2014	James Hilger	CAO	Sell	1,666	$67.23	$112,005.18	13,277
5/15/2014	Javier Rodriguez	CEO	Sell	7,000	$67.50	$472,500.00	64,264
5/12/2014	Dennis Kogod	COO	Sell	32,188	$68.06	$2,190,715.28	59,624
5/8/2014	Dennis Kogod	COO	Sell	32,213	$67.36	$2,169,867.68	59,624
5/7/2014	Michael David Staffieri	COO	Sell	2,633	$67.30	$177,200.90
4/2/2014	Michael David Staffieri	COO	Sell	2,867	$69.15	$198,253.05	2,633
3/20/2014	Laura Mildenberger	Insider	Sell	3,274	$70.04	$229,310.96	6,036
2/26/2014	R. Ted Weschler	major shareholder	Buy	1,159,858	$66.97	$77,675,690.26	2,191,806
2/21/2014	John Nehra	Director	Sell	40,000	$65.81	$2,632,400.00	81,766
2/18/2014	William Roper	Director	Sell	42,519	$66.37	$2,821,986.03	4,994
12/20/2013	Laura Mildenberger	Insider	Sell	10,417	$62.53	$651,375.01	6,036
12/17/2013	Allen Nissenson	Insider	Sell	2,929	$59.83	$175,242.07	2,508
12/9/2013	Berkshire Hathaway Inc	major shareholder	Buy	1,314,170	$57.84	$76,011,592.80
11/8/2013	R. Ted Weschler	major shareholder	Buy	3,700,294	$55.14	$204,034,211.16	1,095,903
7/5/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	110,309	$114.01	$12,576,329.09
7/3/2013	R. Ted Weschler	Major Shareholder	Buy	639,200	$114.78	$73,367,376.00
5/15/2013	David T Shapiro	Insider	Sell	8,779	$129.80	$1,139,514.20
5/15/2013	Dennis Kogod	COO	Sell	21,130	$129.47	$2,735,701.10
5/15/2013	James K Hilger	CFO	Sell	1,049	$130.18	$136,558.82
5/15/2013	Leanne M Zumwalt	VP	Sell	13,209	$129.59	$1,711,754.31
5/13/2013	Kent J Thiry	CEO	Sell	243,307	$129.95	$31,617,744.65
5/13/2013	Kim M Rivera	Insider	Sell	1,672	$129.70	$216,858.40
3/4/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	164,947	$119.59	$19,726,011.73
3/4/2013	Roger Valine	Director	Sell	1,390	$120.00	$166,800.00
2/27/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	211,889	$116.56	$24,697,781.84
2/22/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	224,091	$115.88	$25,967,665.08
2/19/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	323,070	$116.73	$37,711,961.10
2/5/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	32,376	$115.17	$3,728,743.92
2/4/2013	Roger Valine	Director	Sell	1,389	$116.13	$161,304.57
1/16/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	42,400	$111.33	$4,720,392.00
1/15/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	179,300	$109.67	$19,663,831.00
1/10/2013	Berkshire Hathaway Inc	Major Shareholder	Buy	187,898	$109.54	$20,582,346.92
12/24/2012	Dennis Kogod	COO	Sell	12,736	$111.00	$1,413,696.00
12/21/2012	James K Hilger	CFO	Sell	2,073	$112.20	$232,590.60
12/6/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	635,633	$106.20	$67,504,224.60
11/29/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	679,249	$108.20	$73,494,741.80
11/26/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	412,050	$110.38	$45,482,079.00
11/16/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	132,958	$112.45	$14,951,127.10
11/12/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	548,823	$112.15	$61,550,499.45
11/7/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	139,491	$112.03	$15,627,176.73
11/2/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	254,750	$112.20	$28,582,950.00
10/26/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	257,941	$111.14	$28,667,562.74
10/17/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	63,928	$109.56	$7,003,951.68
10/12/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	217,597	$109.76	$23,883,446.72
10/9/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	67,946	$107.71	$7,318,463.66
9/28/2012	Berkshire Hathaway Inc	Major Shareholder	Buy	282,403	$102.03	$28,813,578.09
8/8/2012	Kent J Thiry	Chairman	Sell	320,877	$96.88	$31,086,563.76
8/7/2012	William L Roper	Director	Sell	23,019	$95.95	$2,208,673.05

(Data available from 1/1/2013 forward)

Davita (NYSE DVA) News Headlines

Source:

Date	Headline
	How Highmark and a provider are working to lower the cost of dialysis care finance.yahoo.com - April 24 at 5:38 PM
	DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve ... www.prnewswire.com - April 24 at 8:16 AM
	DaVita and Methodist Specialty and Transplant Hospital Collaborate to Launch Technology Designed to Help Improve Transplant Readiness of Patients finance.yahoo.com - April 24 at 8:16 AM
	DaVita Recognized as a LearningElite Company by Chief Learning Officer Magazine finance.yahoo.com - April 23 at 5:16 PM
	DaVita Releases 10th Annual Community Care Report finance.yahoo.com - April 19 at 8:12 AM
	Buying Binge For UnitedHealth's Optum Is Only Just Beginning finance.yahoo.com - April 18 at 8:12 AM
	Williamsville dialysis center plans new site www.bizjournals.com - April 17 at 6:00 PM
	ION Announces Executive Vice President, Corporate Compliance Officer www.prnewswire.com - April 17 at 8:24 AM
	UnitedHealth raises guidance after 31% profit rise www.marketwatch.com - April 17 at 8:24 AM
	[$$] UnitedHealth Increases Guidance for Year finance.yahoo.com - April 17 at 8:24 AM
	Head-To-Head Survey: Davita (DVA) versus Caladrius Biosciences (CLBS) www.americanbankingnews.com - April 16 at 5:21 PM
	Analyzing Davita (DVA) & Tivity Health (TVTY) www.americanbankingnews.com - April 15 at 5:07 AM
	Brokerages Expect Davita Inc (DVA) Will Post Quarterly Sales of $2.94 Billion www.americanbankingnews.com - April 15 at 4:45 AM
	Davita (DVA) Stock Rating Reaffirmed by Jefferies Group www.americanbankingnews.com - April 13 at 11:43 PM
	Davita (DVA) Lowered to "C+" at TheStreet www.americanbankingnews.com - April 13 at 10:53 AM
	Zacks: Brokerages Expect Davita Inc (DVA) to Announce $0.92 EPS www.americanbankingnews.com - April 13 at 9:01 AM
	DaVita Certified as Freedom-Centered Workplace by WorldBlu www.prnewswire.com - April 12 at 5:42 PM
	Davita Inc (DVA) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - April 12 at 1:34 AM
	30,000 Strong and Counting, UnitedHealth Gathers a Doctor Army finance.yahoo.com - April 9 at 8:14 AM
	Davita (DVA) Downgraded by JPMorgan Chase to Underweight www.americanbankingnews.com - April 7 at 8:50 PM
	Davita (DVA) Receives "Hold" Rating from KeyCorp www.americanbankingnews.com - April 7 at 12:47 PM
	Davita (DVA) PT Set at $57.00 by SunTrust Banks www.americanbankingnews.com - April 7 at 12:31 PM
	DaVita Advocates for Organ Donors to Support Its Patients' Transplant Goals during National Donate Life Month www.streetinsider.com - April 2 at 8:32 AM
	Davita (DVA) Price Target Cut to $60.00 by Analysts at Royal Bank of Canada www.americanbankingnews.com - April 1 at 11:24 AM
	Davita (DVA) Price Target Cut to $66.00 by Analysts at Bank of America www.americanbankingnews.com - April 1 at 9:46 AM
	Davita (DVA) Upgraded to "Buy" at Bank of America www.americanbankingnews.com - March 30 at 4:33 PM
	Specialized Health Services Stocks' Research Reports Released on Acadia Healthcare, DaVita, MEDNAX, and Tivity ... www.prnewswire.com - March 28 at 8:24 AM
	Analysts Anticipate Davita Inc (DVA) to Post $0.92 EPS www.americanbankingnews.com - March 27 at 9:14 AM
	Davita Target of Unusually Large Options Trading (DVA) www.americanbankingnews.com - March 22 at 7:16 AM
	DaVita (DVA) Banks on Kidney Care Unit Amid Labor Union Woes finance.yahoo.com - March 21 at 5:41 PM
	DaVita Kidney Care Shares Seasonal Recipes in New Simply Spring Cookbook finance.yahoo.com - March 21 at 8:42 AM
	Is DaVita (DVA) a Great Stock for Value Investors Right Now? finance.yahoo.com - March 20 at 5:21 PM
	Free Post Earnings Research Report: DaVita’s Quarterly Revenues Rose 3%; EPS Advanced 16% finance.yahoo.com - March 20 at 8:22 AM
	Social Workers Play Vital Role in Patients' Overall Health finance.yahoo.com - March 20 at 8:22 AM
	Renal Physicians Association Honors Dr. Robert Provenzano with Distinguished Nephrology Service Award finance.yahoo.com - March 19 at 8:17 AM
	Davita Inc (DVA) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - March 18 at 1:36 AM
	Davita Sees Unusually Large Options Volume (DVA) www.americanbankingnews.com - March 16 at 7:23 AM
	DaVita Kidney Care Recognizes Its Dietitians on Registered ... - PR Newswire (press release) www.prnewswire.com - March 15 at 8:12 AM
	DaVita Kidney Care Recognizes Its Dietitians on Registered Dietitian Nutritionist Day finance.yahoo.com - March 14 at 7:11 PM
	DaVita Recognized for 11th Consecutive Year Among FORTUNE® Magazine's World's Most Admired Companies® - PR Newswire (press release) www.prnewswire.com - March 12 at 8:42 AM
	DaVita Recognized for 11th Consecutive Year Among FORTUNE® Magazine's World's Most Admired Companies® finance.yahoo.com - March 12 at 8:42 AM
	Zacks: Brokerages Anticipate Davita Inc (DVA) Will Announce Earnings of $0.91 Per Share www.americanbankingnews.com - March 10 at 3:34 AM
	See what the IHS Markit Score report has to say about Davita Inc. finance.yahoo.com - March 9 at 8:15 AM
	DaVita Hosts Panel to Promote Women's Health and Empowerment on World Kidney Day - PR Newswire (press release) www.prnewswire.com - March 8 at 8:18 AM
	DaVita Hosts Panel to Promote Women's Health and Empowerment on World Kidney Day finance.yahoo.com - March 8 at 8:18 AM
	DaVita Celebrates National Nutrition Month with Online Kidney Diet Resources - PR Newswire (press release) www.prnewswire.com - March 6 at 8:12 AM
	DaVita Celebrates National Nutrition Month with Online Kidney Diet Resources finance.yahoo.com - March 6 at 8:12 AM
	Calamos Advisors LLC Sells 806 Shares of Davita Inc (DVA) www.americanbankingnews.com - March 6 at 5:22 AM
	Davita Inc (DVA) Shares Bought by American International Group Inc. www.americanbankingnews.com - March 6 at 4:24 AM
	Stonerise Capital Management LLC Buys New Position in Davita Inc (DVA) www.americanbankingnews.com - March 4 at 2:59 PM

Davita (NYSE:DVA) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Davita (NYSE:DVA) Income Statement, Balance Sheet and Cash Flow Statement

Davita (NYSE DVA) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff